MarginsXMarginsX
Home › Markets › Industrials › HBIO

Harvard Bioscience Inc. (HBIO)

HBIO trades on Nasdaq in Industrials, Biotechnology: Laboratory Analytical Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$8.91
-5.96% on the day
Market cap
$40.7M
Nano cap
Revenue · 2025
$86.5M
-8.1% on 2024
Net income · 2025
-$56.7M
-65.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1123494/000117184326001548/0001171843-26-001548-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerHBIO on Nasdaq
SectorIndustrials
IndustryBiotechnology: Laboratory Analytical Instruments
CountryUnited States
IPO year2000
SEC CIK0001123494
SEC industry codeLaboratory Analytical Instruments
Incorporated inDE

Financials · 2025

LineValue
Revenue$86.5M
Net income-$56.7M
Operating income-$48.6M
Net margin-65.5%
Operating margin-56.1%
Revenue growth-8.1%
Cash$8.6M
Total assets$80.1M
P/E (computed)Net income was not positive
P/S (computed)0.5×

Warning signs

Cash runway
85.6 months
$4.9M cash at September 30, 2026
Share count, 1 year
+2.6%
2025-11-03 to 2026-11-03 · +7.1% over 3 years
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
$202K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Although management has identified the existence of adverse conditions with respect to its liquidity, including recurring net losses, negative cash flows from operating activities and a decline in cash and cash equivalents, it has concluded that these conditions, when considered in the aggregate, do not raise substantial doubt about the Company's ability to continue as a going concern within twelve months from the is"
10-Q 2026-11-10
Cash and burn$4.9M cash; operating cash flow -$170K a quarter.Report 2026-09-30
Shares outstanding4,573,080 (2026-11-03); 44,579,665 a year earlier; 42,688,246 three years earlier. 1y figure adjusted for splits (1-for-10 overall); 3y figure adjusted for splits (1-for-10 overall).Cover page 2026-11-03
Reverse splits, 3 years1; latest 1-for-10 on 2026-03-16Source 2026-03-16
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-01-30
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorGrant Thornton LLP, Hartford, Connecticut, United StatesPCAOB Form AP 2026-03-19
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $202K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$22.2M-$2.6M-$248K$4.9M$37.2M$89.4M10-Q 2026-11-10
Q2 2026
2026-06-30
$22.7M-$2.9M$325K$6.5M$36.7M$87.8M10-Q 2026-08-11
Q1 2026
2026-03-31
$20.8M-$3.4M-$662K$7.1M$36.2M$85.5M10-Q 2026-05-12
Q4 2025
2025-12-31
$23.7M-$2.8M-$96K$8.6M$35.9M$86.5M10-K 2026-03-13
Q3 2025
2025-09-30
$20.6M-$1.2M$1.1M$6.8M$34.0M$87.4M10-Q 2026-11-10
Q2 2025
2025-06-30
$20.4M-$2.3M$2.8M$7.4M$34.9M$88.8M10-Q 2026-08-11
Q1 2025
2025-03-31
$21.8M-$50.3M$3.0M$5.5M$36.4M$91.4M10-Q 2026-05-12
Q4 2024
2024-12-31
$24.6M$18K$1.7M$4.1M$37.0M$94.1M10-K 2026-03-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM 424B3
424B32026-02-09
Latest annual report
FORM 10-K
10-K2026-03-13
Latest quarterly / interim
FORM 10-Q
10-Q2026-11-10
Latest current report
FORM 8-K
8-K2026-11-10
Latest proxy
FORM DEFA14A
DEFA14A2026-04-21

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+12.3%
1 month+13.5%
3 months+40.8%
Year to date+40.1%
1 year+61.9%
From 52-week high-3.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Laboratory Analytical Instruments

TickerCompanyPriceDayMarket cap
RPIDRapid Micro Biosystems Inc.$0.7400+13.67%$37.1M
PRPOPrecipio Inc.$19.96-9.81%$35.8M
EYPTEyePoint Inc.$0.3076+0.52%$35.0M
SEERSeer Inc.$1.48-5.73%$82.6M
CIRCCircle8 Group Inc.$0.1702-7.30%$20.0M
BNGOBionano Genomics Inc.$0.9400-6.00%$13.1M
QTRXQuanterix Corporation$2.84-3.07%$134.8M
ASTCAstrotech Corporation (DE)$3.76-10.48%$8.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier